

Cancer
Specialised Cancer Surgery
Stereotactic Radiosurgery and Stereotactic Radiotherapy (Intracranial) (All Ages)

D05/S/a

Code	Metric	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Notes	Q1	Q2	Q3	Q4
ST01a	Number of Tier 1 and 2 patients treated with SRS/SRT	Total number of Tier 1 and Tier 2 patients treated with SRS/SRT in the reporting period		Rolling annual	Quarterly	Provider		100	Include: any patients treated whether as initial treatment or as 'retreatment'. If a patient received more than 1 treatment in reporting period count as separate. The data required is per delivery site and treatment platform.	Jul-21 - Jun-22	Oct-21 - Sep-22	Jan-22 - Dec-22	Apr-22 - Mar-23
ST01b	Number of Tier 3 and 4 patients treated with SRS/SRT	Total number of Tier 3 and Tier 4 patients treated with SRS/SRT in the reporting period		Rolling annual	Quarterly	Provider			Include: any patients treated whether as initial treatment or as 'retreatment'. If a patient received more than 1 treatment in reporting period count as separate. The data required is per delivery site and treatment platform.	Jul-21 - Jun-22	Oct-21 - Sep-22	Jan-22 - Dec-22	Apr-22 - Mar-23
ST01c	Number of paediatric oncology patients treated with SRS/SRT	Total number of paediatric oncology patients treated with SRS/SRT in the reporting period		Rolling annual	Quarterly	Provider			Include: any patients treated whether as initial treatment or as 'retreatment'. If a patient received more than 1 treatment in reporting period count as separate. Paediatric oncology patients aged 0 to 15 years, up to their 16th birthday. The data required is per delivery site and treatment platform.	Jul-21 - Jun-22	Oct-21 - Sep-22	Jan-22 - Dec-22	Apr-22 - Mar-23
ST01d	Number of Teenagers & Young Adults (TYA) patients treated with SRS/SRT	Total number of TYA patients treated with SRS/SRT in the reporting period		Rolling annual	Quarterly	Provider			Include: Any patients treated whether as initial treatment or as 'retreatment'. If a patient received more than 1 treatment in reporting period count as separate. TYA patients aged from 16 to the end of their 24th year. The data required is per delivery site and treatment platform.	Jul-21 - Jun-22	Oct-21 - Sep-22	Jan-22 - Dec-22	Apr-22 - Mar-23
ST02	Proportion of patients whose outcome has been communicated to the referring Consultant/MDT and the General Practitioner (GP) within 2 working days of the SRS/SRT MDT meeting	Of those in the denominator, the number of patients whose outcome has been communicated to the referring Consultant/MDT the GP within 2 working days of the SRS/SRT MDT meeting	Total number of Tier 1, Tier 2, Tier 3 and Tier 4 patients discussed at the SRS/SRT MDT in the reporting period	Quarter	Quarterly	Provider	Provider		The data required is per delivery site and treatment platform.	Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22	Jan-23 - Mar-23
ST03	Proportion of patients with malignant disease for SRS/SRT that received a clinical review within 1 week of the Neurosciences (Neuro-oncology) MDT meeting	Of those in the denominator, the number of patients who received a clinical review within 1 week of the Neurosciences (Neuro-oncology) MDT meeting	Total number of patients with malignant disease discussed at the Neurosciences (Neuro-oncology) MDT meeting and recommended as to be considered as a candidate for SRS/SRT treatment in the reporting period	Quarter	Quarterly	Provider	Provider		Time to clinical review: 1 week from the date of the Neurosciences (Neuro-oncology) MDT meeting to the date of the clinical review. The data required is per delivery site and treatment platform.	Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22	Jan-23 - Mar-23
ST04	Proportion of patients with malignant disease with SRS/SRT treatment delivered within 2 weeks of the decision to treat (in clinic)	Of those in the denominator, the number of patients whose treatment was delivered within 2 weeks of the decision to treat (in clinic)	Total number of patients with malignant disease treated with SRS/SRT in the reporting period	Quarter	Quarterly	Provider	Provider		Time to treatment: 2 weeks from the date that the decision to treat was agreed with the patient in clinic to the date of treatment. The data required is per delivery site and treatment platform.	Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22	Jan-23 - Mar-23

Cancer
Specialised Cancer Surgery
Stereotactic Radiosurgery and Stereotactic Radiotherapy (Intracranial) (All Ages)

D05/S/a

Code	Metric	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Notes	Q1	Q2	Q3	Q4
ST05	Percentage of mortality within 30 days following SRS/SRT treatment	Of those in the denominator, the number of patients who died within 30 days following SRS/SRT treatment	Total number of patients treated with SRS/SRT in the reporting period	Rolling annual	Quarterly	Provider	Provider		The data required is per delivery site and treatment platform. This mortality data is not standardised.	Jul-21 - Jun-22	Oct-21 - Sep-22	Jan-22 - Dec-22	Apr-22 - Mar-23
ST06	Proportion of patients with malignant disease treated with SRS/SRT with a Karnofsky Performance Status (KPS) <70	Of those in the denominator, the number of patients with a performance status KPS <70	Total number of patients with malignant disease treated with SRS/SRT in the reporting period	Quarter	Quarterly	Provider	Provider		The data required is per delivery site and treatment platform.	Apr-22 - Jun-22	Jul-22 - Sep-22	Oct-22 - Dec-22	Jan-23 - Mar-23
ST07	Proportion of patients with malignant disease that developed a permanent neurological deficit within 6 months of SRS/SRT treatment	Of those in the denominator, the number of patients that developed a permanent neurological deficit within 6 months of SRS/SRT treatment	Total number of patients with malignant disease treated with SRS/SRT in the reporting period	Annual	Annual	Provider	Provider		The data required is per delivery site and treatment platform.	N/A	N/A	N/A	Oct-21 - Sep-22
ST08	Proportion of patients with cerebral metastases who require retreatment or alternative surgical treatment on the same lesion within 12 months of SRS/SRT treatment	Of those in the denominator, the number of patients that required retreatment or alternative surgical treatment on the same lesion, within 12 months	Total number of patients with cerebral metastases treated with SRS/SRT in the reporting period	Annual	Annual	Provider	Provider		The data required is per delivery site and treatment platform.	N/A	N/A	N/A	Apr-21 - Mar-22
ST09	Proportion of patients with meningioma that required a course of steroids for symptomatic oedema within 6 months following SRS/SRT treatment	Of those in the denominator, the number of patients who required a course of steroids within 6 months following SRS/SRT treatment for symptomatic oedema	Total number of patients with meningioma treated with SRS/SRT in the reporting period	Annual	Annual	Provider	Provider		The data required is per delivery site and treatment platform.	N/A	N/A	N/A	Oct-21 - Sep-22
ST10	Proportion of patients with skull base tumours treated with SRS/SRT with a new or worsened cranial nerve deficit within the 12 months following SRS/SRT treatment	Of those in the denominator, the number of patients with a new or worsened cranial nerve deficit within the 12 months following SRS/SRT treatment	Total number of patients with skull base tumours treated with SRS/SRT in the reporting period	Annual	Annual	Provider	Provider		New or worsened cranial nerve deficits include a change in hearing from serviceable to non-serviceable, new or worsened facial nerve function and numbness. The data required is per delivery site and treatment platform.	N/A	N/A	N/A	Apr-21 - Mar-22
ST11	Proportion of patients with complete obliteration of Arteriovenous Malformations (AVM) on 3 year angiogram	Of those in the denominator, the number of patients with complete obliteration of AVM on 3 year angiogram	Total number of AVM patients having a 3 year angiogram in the reporting period	Annual	Annual	Provider	Provider		The data required is per delivery site and treatment platform.	N/A	N/A	N/A	Apr-22 - Mar-23
ST12a	Proportion of patients with hormone secreting tumours with normalisation within 12 months after SRS/SRT treatment	Of those in the denominator, the number of patients with normalisation within 12 months after SRS/SRT treatment	Total number of patients with hormone secreting tumours treated with SRS/SRT in the reporting period	Annual	Annual	Provider	Provider		Normalisation means to within normal levels, accepted in the definition of cure. The data required is per delivery site and treatment platform.	N/A	N/A	N/A	Apr-21 - Mar-22
ST12b	Proportion of patients with a new visual field deficit and/or cranial nerve deficit 12 months post SRS/SRT treatment for pituitary adenomas	Of those in the denominator, the number of patients with a new visual field deficit and/or cranial nerve deficit within the 12 months following SRS/SRT treatment	Total number of patients with pituitary adenomas treated with SRS/SRT in the reporting period	Annual	Annual	Provider	Provider		The data required is per delivery site and treatment platform.	N/A	N/A	N/A	Apr-21 - Mar-22
ST13a	Proportion of patients with trigeminal neuralgia reporting a reduction of 1 or more points on the Barrow Neurological Institute Pain Intensity Score at 1 year post SRS/SRT treatment, compared to pre-treatment measurement	Of those in the denominator, the number of patients reporting a reduction of 1 or more points on the Barrow Neurological Institute Pain Intensity Score at 1 year post SRS/SRT treatment compared to pre-treatment measurement	Total number of patients with trigeminal neuralgia treated with SRS/SRT in the reporting period	Annual	Annual	Provider	Provider		The Barrow score is: 0 - no pain no meds, 1 - occasional pain no meds, 2 - some pain but controlled with meds, 3 - some pain not controlled with meds, 4 - Severe pain or no pain relief. The data required is per delivery site and treatment platform.	N/A	N/A	N/A	Apr-21 - Mar-22
ST13b	Proportion of patients with anesthesia dolorosa at 1 year following SRS/SRT treatment for trigeminal neuralgia	Of those in the denominator, the number of patients diagnosed with anesthesia dolorosa at 1 year following SRS/SRT treatment	Total number of patients with trigeminal neuralgia treated with SRS/SRT in the reporting period	Annual	Annual	Provider	Provider		The data required is per delivery site and treatment platform.	N/A	N/A	N/A	Apr-21 - Mar-22

Cancer
Specialised Cancer Surgery
Stereotactic Radiosurgery and Stereotactic Radiotherapy (Intracranial) (All Ages)

D05/S/a

Code	Metric	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Notes	Q1	Q2	Q3	Q4
ST13c	Proportion of patients with trigeminal neuralgia requiring other treatments, within the 12 months following SRS/SRT treatment	Of those in the denominator, the number of patients requiring other treatments within the 12 months following SRS/SRT treatment	Total number of patients with trigeminal neuralgia treated with SRS/SRT in the reporting period	Annual	Annual	Provider	Provider		Other treatments: where other interventional or surgical or medical treatment required. The data required is per delivery site and treatment platform.	N/A	N/A	N/A	Apr-21 - Mar-22
ST14	Proportion of patients treated with SRS/SRT given a Quality of Life (QOL)/Patient Survey to complete	From the denominator, the number of patients given a Quality of Life (QOL)/Patient Survey to complete	Total number of patients treated with SRS/SRT in the reporting period	Annual	Annual	Provider	Provider		Quality of Life (QOL)/Patient Surveys being given to measure quality of life before and after SRS/SRT treatment. A patient may be given more than one Quality of Life (QOL)/Patient Survey, but must only be counted The data required is per delivery site and treatment platform.	N/A	N/A	N/A	Apr-22 - Mar-23
ST15	Proportion of patients recruited into SRS/SRT trials (where SRS/SRT is a component of a trial)	Of those in the denominator, the number of patients recruited into trials (where SRS/SRT is a component of the trial)	Total number of patients treated with SRS/SRT in the reporting period	Annual	Annual	Provider	Provider		The data required is per delivery site and treatment platform.	N/A	N/A	N/A	Apr-22 - Mar-23
ST16	Rate of formal complaints received	Total number of formal complaints received relating to the SRS/SRT service during the reporting period	Total number of patients referred to the SRS/SRT service in the reporting period	Annual	Annual	Provider	Provider		Numerator note: each provider organisation will have a formal complaints process where complaints are logged, registered and tracked. Include any formal complaints received relating to the SRS/SRT service (for any patients referred to the SRS/SRT service). Providers to include all patients referred to the SRS/SRT service and not just patients treated with SRS/SRT. The data required is per delivery site and treatment platform.	N/A	N/A	N/A	Apr-22 - Mar-23